Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells

Area of Science:

• Cardiovascular Biology
• Metabolic Disease Research
• Pharmacology

Background:

• Sodium-glucose cotransporter 2 (SGLT2) inhibitors show promise as cardioprotective agents.
• The direct effects of SGLT2 inhibitors on cardiomyocyte injury mechanisms remain under investigation.

Purpose of the Study:

• To elucidate the molecular mechanisms by which empagliflozin (EMPA) mitigates palmitate (PA)-induced cardiomyocyte injury.
• To explore EMPA's impact on cellular stress pathways and metabolic function in cardiomyocytes.

Main Methods:

• Utilized H9c2 cell line to model palmitate-induced cardiomyocyte injury.
• Assessed the effects of EMPA on insulin sensitivity, endoplasmic reticulum (ER) stress, inflammatory markers, and apoptosis.
• Measured intracellular AMP levels, AMPK pathway activation, and carnitine palmitoyl transferase 1 (CPT1) gene expression.

Main Results:

• EMPA significantly attenuated PA-induced impairments in insulin sensitivity, ER stress, inflammation, and apoptosis.
• EMPA treatment led to increased AMP levels and activated the AMPK pathway.
• EMPA enhanced fatty acid oxidation by increasing CPT1 gene expression, thereby reducing cellular stress.

Conclusions:

• Empagliflozin exerts cardioprotective effects against palmitate-induced cardiomyocyte injury through a novel mechanism.
• EMPA improves cellular metabolism and reduces stress, offering therapeutic potential for heart conditions.